Morphotek was recently acquired by Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., to operate as an independent subsidiary in developing therapeutic antibodies for cancer, inflammation and infectious diseases.
Over its six year history, Morphotek has successfully raised $78 million in venture capital, most recently closing a $40 million Series D financing in October of 2006. In April 2007, the company was acquired by Eisai for $325 million plus net excess cash on the company balance sheet. It’s CEO, Dr. Nicolas Nicolaides, has recently been named one of the Top 20 Scientists in R&D by R&D Directions, a bi-monthly magazine that provides readers with extensive knowledge of compounds progressing through the pharmaceutical pipeline as well as the companies developing these compounds. Morphotek has also been named on of the Top Three Fastest Growing Companies in the Philadelphia region by the Philadelphia 100®, a yearly event hosted by the Entrepreneurs Forum of Greater Philadelphia, the Philadelphia Business Journal and the Wharton SBDC which honors the fastest growing, privately-held companies in the Greater Philadelphia Region.
For more information about Morphotek, visit their website at www.morphotek.com